Key facts
- It has raised $250K; the latest was Early Stage VC in Dec 2025.
- Notable investors include Plug and Play Tech Center, The Engine, New York Ventures, Camford Capital, Milemark.capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Collage (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Collage (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Collage (Drug Discovery)
Developer of a novel class of polynucleotide therapeutics designed to unlock the full potential of ribonucleic acid (RNA) medicine. The company offers AI-enhanced RNA engineering with specificity and programmability, and regulates gene expression, enabling patients with previously untreatable diseases access to scalable, reversible, and durable treatments.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Employees
- 4
- Website
- collagebio.com/
- Ownership
- Privately Held (backing)
Collage (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Collage (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Collage (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.